A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This study of NicaPlant® is conducted in patients who have a subarachnoid haemorrhage.
Patients will be randomized in two treatment groups. Both groups will receive the standard of
care and the investigational group will receive in addition NicaPlant®. NicaPlant® is tested
to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).
Phase:
Phase 2
Details
Lead Sponsor:
BIT Pharma GmbH
Collaborators:
Data Magik Limited NeuroScios GmbH Pharm-Analyt Labor GmbH